The Ingredient Guide: What Your Skin Barrier Actually Needs

Ceramides are the primary structural lipids of the skin barrier, accounting for approximately 50% of the lamellar bilayer matrix by molar composition. At least 12 distinct subtypes are present in human skin. They are synthesized by keratinocytes and secreted into the intercellular space via lamellar bodies during the final stages of epidermal differentiation.

Topically applied ceramides can penetrate the stratum corneum and partially restore the lamellar bilayer architecture. The evidence is most robust for formulations containing multiple ceramide subtypes — particularly CER NP, CER AP, and CER EOS — applied in combination with cholesterol and free fatty acids. Ceramides alone, without the other two barrier lipids, show measurably weaker repair outcomes in comparative studies because the lamellar bilayer cannot form correctly from a single lipid class.

The concentration required for clinical effect is lower than in most food or pharmacological applications because the target tissue is the very surface the product touches. Concentrations of 0.01–0.3% (measured across the ceramide complex, not individual subtypes) have demonstrated statistically significant reductions in TEWL. The delivery system matters as much as the concentration: MVE (multivesicular emulsion) technology shows superior sustained-release profiles versus standard emulsions.

• Directly restores lamellar bilayer structure
• Reduces transepidermal water loss (TEWL)
• Shown to reduce eczema flare frequency with consistent use
• No known side effects or contraindications at topical concentrations
• Safe throughout pregnancy and breastfeeding

What ceramides cannot do: They do not reduce existing inflammation (that is a job for anti-inflammatory actives), do not treat infection, and are not sufficient as a sole treatment for active inflammatory conditions like eczema flares — they work best as maintenance and prevention.

Niacinamide is the amide form of vitamin B3 and one of the most functionally versatile ingredients in evidence-based skincare. Unlike most topical actives, it is effective across a wide pH range, is stable in formulation, and has a well-established safety profile across skin tones and skin types including sensitive and rosacea-prone skin.

Its primary mechanism for barrier repair is stimulation of ceramide synthesis. Niacinamide increases the activity of serine palmitoyl transferase — the rate-limiting enzyme in ceramide biosynthesis — leading to measurably increased ceramide production within keratinocytes over a 4–8 week treatment period. This makes it one of the few topical ingredients that works from within the epidermis rather than simply supplementing lipids from outside.

Secondary mechanisms include: inhibition of melanosome transfer between melanocytes and keratinocytes (reducing hyperpigmentation and post-inflammatory marks), reduction of inflammatory cytokine release from mast cells (relevant in rosacea and eczema), and sebum regulation through reduction of sebocyte lipid synthesis. The last mechanism is concentration-dependent: 2–4% for anti-inflammatory and barrier effects, 5% for skin tone improvement, 10% for pore and sebum effects.

The concern about niacinamide causing flushing arises from early studies on high-dose oral nicotinic acid (a different B3 form) and is not supported by topical evidence. Conversion from niacinamide to nicotinic acid in products is minimal and the resulting niacin content is far below the threshold for vascular effects. However, a small minority of individuals with very reactive skin do report mild flush at concentrations above 5% — starting at 2% and increasing is a sensible precaution for this group.

• Stimulates ceramide synthesis from within the epidermis
• Reduces inflammatory mediator release in rosacea and eczema
• Improves post-inflammatory hyperpigmentation across skin tones
• Stabilizes the skin barrier over consistent 4–8 week use
• Compatible with most other actives including retinoids and vitamin C

What niacinamide cannot do: It does not exfoliate, does not significantly increase skin cell turnover, and will not produce the visible short-term "glow" of an AHA. Its benefits are cumulative and require 4–8 weeks of consistent use to be measurable. Stopping use reverses the barrier synthesis benefit over the following ceramide cycle.

Hyaluronic acid (HA) is a glycosaminoglycan — a long-chain sugar molecule — naturally abundant in the extracellular matrix of the dermis, where it binds up to 1,000 times its weight in water and maintains dermal volume and skin fullness. It is not, in the traditional sense, a barrier repair ingredient: its primary function is humectancy, drawing water from deeper skin layers and from the environment into the stratum corneum.

The most important variable in topical HA is molecular weight, not concentration. High molecular weight HA (above 500 kDa) cannot penetrate the stratum corneum and sits on the skin surface, providing surface-level moisturization but no structural benefit. Low molecular weight HA (below 50 kDa) can penetrate into the upper stratum corneum and has been shown in clinical studies to improve skin hydration at depth and modestly reduce TEWL. Very low molecular weight HA fragments (oligomeric HA, below 6 kDa) penetrate further and have documented anti-inflammatory and wound-healing properties at the expense of some potential irritation in sensitive skin.

The best HA formulations for barrier support combine multiple molecular weights — a high-MW fraction for immediate surface hydration and a low-MW fraction for deeper penetration. Humectants including HA require an occlusive or emollient to function effectively: if applied to the skin surface without a follow-up occlusive layer, HA can draw water out of the deeper epidermis toward the dry environment, paradoxically increasing TEWL in very low-humidity conditions.

• Immediate and measurable increase in skin hydration
• Improves the feel and appearance of dryness within minutes of application
• Low molecular weight fractions show modest TEWL reduction
• Compatible with all other actives and skin types
• No known side effects at topical concentrations

What hyaluronic acid cannot do: It does not rebuild the lipid barrier. It does not reduce inflammation. It does not produce results equivalent to ceramide repair for barrier-damaged skin. It is a hydration tool, not a repair tool, and should be layered under an emollient or moisturiser to function optimally.

Panthenol is the alcohol analog of pantothenic acid (vitamin B5) and converts to pantothenic acid within the skin, where it functions as a cofactor in cellular energy metabolism. Its presence in skincare formulations predates most modern active ingredients — it has been used in wound care, post-procedure healing, and dermatitis management for decades, with a well-established evidence base.

The primary mechanism relevant to barrier repair is stimulation of fibroblast proliferation and collagen synthesis in the dermis, combined with a direct effect on epidermal cell migration and keratinocyte differentiation. Multiple in vitro and in vivo studies have demonstrated that panthenol at concentrations of 1% and above accelerates wound re-epithelialization and restores barrier function after disruption more rapidly than vehicle alone.

Panthenol also has documented humectant properties — its molecular structure allows it to bind water within the stratum corneum — and measurable anti-inflammatory effects, reducing the production of pro-inflammatory cytokines including IL-1 and TNF-alpha in challenged skin. The combination of wound-healing stimulation, humectancy, and anti-inflammation makes it particularly valuable during the acute recovery phase of barrier damage.

It is among the most universally well-tolerated ingredients across all skin types, with an essentially zero contact sensitization rate in patch testing studies. This distinguishes it from most other active ingredients, which carry finite sensitization risk with repeated exposure.

• Accelerates wound healing and barrier re-epithelialization
• Reduces pro-inflammatory cytokines (IL-1, TNF-alpha)
• Humectant: improves skin hydration at depth
• Virtually no sensitization risk — among the safest topical actives
• Suitable for the most compromised, reactive skin states

What panthenol cannot do: It does not directly replace ceramides or structural lipids. Its effects on barrier architecture are indirect, via stimulation of the skin's own synthesis pathways rather than direct lipid supplementation. At concentrations below 1%, clinical benefit is uncertain.

Centella asiatica is a tropical plant that has been used in wound healing in Ayurvedic and traditional Asian medicine for centuries. Modern research has isolated its active compounds — primarily the triterpenoids asiaticoside, madecassoside, asiatic acid, and madecassic acid — and characterized their mechanisms with increasing precision over the past two decades.

The most well-established mechanism is stimulation of type I and type III collagen synthesis via activation of TGF-beta signaling pathways. This makes centella relevant not just to surface barrier repair but to the structural integrity of the underlying dermis — the layer that gives skin its firmness and resilience. In the stratum corneum specifically, the triterpenoids reduce inflammatory cascade activation by inhibiting NF-kB signaling — a master regulator of the inflammatory response that drives many skin conditions including eczema and rosacea.

Madecassoside has attracted particular interest for its ability to reduce transepidermal water loss in compromised skin and promote the recovery of barrier function after chemical disruption in murine models. Asiaticoside shows wound-healing acceleration through enhanced fibroblast activity and angiogenesis modulation. The combination of these mechanisms — reduced inflammation, accelerated repair, and collagen support — makes centella asiatica one of the few topical ingredients that addresses multiple layers of skin structure simultaneously.

The CICA trend in K-beauty skincare is partially justified by this evidence, though formulations vary enormously in which centella fractions they contain and at what concentration. A product claiming "centella" on its label may contain whole-plant extract (cheaper, less standardized) or isolated triterpenoids (more expensive, more clinically predictable). For active barrier damage recovery, isolated madecassoside or asiaticoside at 0.1%+ is preferable to generic "centella extract."

• Reduces NF-kB inflammatory signaling
• Stimulates collagen synthesis via TGF-beta pathway
• Accelerates wound healing and barrier re-epithelialization
• Reduces TEWL in compromised skin models
• Well tolerated; occasional sensitivity in those allergic to Apiaceae plant family

What centella asiatica cannot do: It does not replace structural lipids and will not repair a ceramide deficit on its own. Anti-inflammatory activity, however potent, does not substitute for barrier lipid restoration in conditions like eczema where the primary deficit is structural. Best used as a complement to a ceramide moisturiser, not a replacement for one.